Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Emory University · University of Pennsylvania · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
849
total citations
- FWCI
- 86.32
- Percentile
- 100%
- References
- 25
Citations per year
Authors
32Topics & keywords
Topics
Keywords
- Daratumumab
- Medicine
- Multiple myeloma
- Refractory (planetary science)
- Internal medicine
- Clinical endpoint
- Clinical trial
- Phases of clinical research
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.